Xerion Limited is an Australian-based specialty pharmaceutical company focused on revolutionising standard of care in dermatology through the development of innovative therapies.
The company’s product portfolio includes a robust pipeline of dermatological products being developed specifically for the US prescription market. Xerion has already launched over the counter (OTC) products broadly ranged in pharmacies in Australia, New Zealand and sold online in the USA. nailKALM is proven and TGA approved to treat fungal nail disease, and early clinical evidence indicates potential for the treatment of acne, atopic dermatitis, psoriasis, rosacea and actinic keratosis (pre-basal cell carcinoma).
Xerion Limited also has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide, which has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals. One application for this technology is its utility as a companion diagnostic tool for the high value consumer supplement market for which we have a distribution agreement with BASF, a large global player.
The company’s product portfolio includes proprietary algae bioactives and TGA approved anti-fungal products:
- AMYCOT®: algal complex mix of bioactives with anti-fungal, anti-bacterial, anti-inflammatory and skin-repair properties.
- KALM: Xerion’s lead product, a topical anti-fungal product line.
- PUFAcoat: a proprietary dried blood spot (DBS) which stabilises fatty acids for long periods of time in ambient conditions facilitating the accurate measurement of fatty acids and is a useful tool in determining the Omega 3 Index.
Xerion has a robust product pipeline and research partnerships to extend its product range and indications.